Elovaren’s pipeline takes small molecules with established human exposure into defined rare neurological, neurodevelopmental, and metabolic indications — trading discovery risk for regulatory execution.
Most of what makes rare-disease development expensive is discovery risk — and most of that risk is already retired for a molecule that has been in people.
Each candidate is a small molecule already administered to people, with safety and pharmacokinetics characterized in the published record. The questions that consume the largest share of a discovery-stage budget are substantially answered before a program begins.
Programs are advanced to FDA designation first. A designation is a regulatory position with standing, and it is reached on a small fraction of what a registrational trial costs. Our first program holds an FDA rare pediatric disease designation.
Each program targets one indication with a defined patient population and a documented unmet need. Narrow scope is what keeps the development path legible to a reviewer and to a partner.
Programs centered on defined patient populations, focused development strategies, and substantial unmet need.
| Program | Indication | Candidate | Regulatory milestone |
|---|---|---|---|
| MGAM-003Classic PMD | Classic Pelizaeus-Merzbacher diseaseRare pediatric disease | Clemastine fumarate | Rare Pediatric Disease Designation granted |
| Gradus Neurology | Unannounced | Unannounced | Unannounced |
